{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T02:07:17Z","timestamp":1781921237886,"version":"3.54.5"},"reference-count":136,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Clin Med Insights Oncol"],"published-print":{"date-parts":[[2012,1]]},"abstract":"<jats:p>Hormone ablation therapy (HALT) for breast or prostate cancer accelerates the development of osteoporosis in both men and women by causing estrogen deficiency, which increases the risk for fracture by promoting bone resorption mediated by osteoclasts. Denosumab, a fully human monoclonal antibody that inhibits osteoclast formation and function, increases bone mass in patients undergoing hormone ablation therapy. In the HALT study of 1,468 men with prostate cancer on androgen-deprivation therapy, denosumab significantly reduced the risk of new vertebral fractures, increased bone mineral density (BMD), and reduced markers of bone turnover. In a study of 252 women with breast cancer undergoing adjuvant aromatase inhibitor (AI) therapy, denosumab increased BMD at 12 and 24 months, overall and in all patient subgroups. The overall rates of adverse events were similar to placebo. Clinicians should consider fracture risk assessment and therapies such as denosumab to increase bone mass in patients on hormone ablation therapy who are at high risk for fracture.<\/jats:p>","DOI":"10.4137\/cmo.s8511","type":"journal-article","created":{"date-parts":[[2012,8,16]],"date-time":"2012-08-16T17:14:39Z","timestamp":1345137279000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":30,"title":["Treatment-Induced Bone Loss and Fractures in Cancer Patients Undergoing Hormone Ablation Therapy: Efficacy and Safety of Denosumab"],"prefix":"10.4137","volume":"6","author":[{"given":"Allan","family":"Lipton","sequence":"first","affiliation":[{"name":"College of Medicine, Penn State Hershey Medical Center, Hershey, PA, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew R.","family":"Smith","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital Cancer Center, Boston, MA, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgiana K.","family":"Ellis","sequence":"additional","affiliation":[{"name":"Seattle Cancer Care Alliance, Seattle, WA, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Goessl","sequence":"additional","affiliation":[{"name":"Amgen Inc. Thousand Oaks, CA, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2012,8,16]]},"reference":[{"key":"bibr1-CMO.S8511","author":"International Agency for Research on Cancer (IARC).","year":"2010","journal-title":"GLOBOCAN"},{"key":"bibr2-CMO.S8511","author":"International Agency for Research on Cancer (IARC).","year":"2010","journal-title":"GLOBOCAN"},{"key":"bibr3-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djn233"},{"key":"bibr4-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000134888.22332.bb"},{"key":"bibr5-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2010.10.039"},{"key":"bibr6-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq174"},{"key":"bibr7-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.10.1949"},{"key":"bibr8-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1016\/j.acuro.2011.03.011"},{"key":"bibr9-CMO.S8511","unstructured":"National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Prostate Cancer. V3.2012. http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf."},{"key":"bibr10-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1001\/jama.294.2.238"},{"key":"bibr11-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1014618"},{"key":"bibr12-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1023\/A:1020299707510"},{"key":"bibr13-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr371"},{"key":"bibr14-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.3756"},{"key":"bibr15-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.08.017"},{"key":"bibr16-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1188\/07.ONF.55-63"},{"key":"bibr17-CMO.S8511","unstructured":"National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Breast Cancer. V1.2012. http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf. Accessed Jun 14, 2012."},{"key":"bibr18-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2011.06.020"},{"key":"bibr19-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr372"},{"key":"bibr20-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70389-8"},{"key":"bibr21-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.11.0726"},{"key":"bibr22-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2004.09.005"},{"key":"bibr23-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2048"},{"key":"bibr24-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.01.174"},{"key":"bibr25-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra030831"},{"key":"bibr26-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2009.0080"},{"key":"bibr27-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1084\/jem.173.5.1291"},{"key":"bibr28-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1038\/nature01658"},{"key":"bibr29-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1101\/gad.13.18.2412"},{"key":"bibr30-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)81569-X"},{"key":"bibr31-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1210\/edrv.23.3.0465"},{"key":"bibr32-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2009.112"},{"key":"bibr33-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022464"},{"key":"bibr34-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2007-1876"},{"key":"bibr35-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-1740"},{"key":"bibr36-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-0856"},{"key":"bibr37-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20056"},{"key":"bibr38-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(00)00895-5"},{"key":"bibr39-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1002\/pds.2258"},{"key":"bibr40-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2009.0076"},{"key":"bibr41-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.7.1570"},{"key":"bibr42-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.20826"},{"key":"bibr43-CMO.S8511","unstructured":"International Osteoporosis Foundation. Facts and statistics about osteoporosis and its impact. 2011; http:\/\/www.iofbonehealth.org\/facts-and-statistics.html. Accessed Jan 22, 2012."},{"key":"bibr44-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.0923"},{"key":"bibr45-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21335"},{"key":"bibr46-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.165.5.552"},{"key":"bibr47-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6690188"},{"key":"bibr48-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(07)70385-6"},{"key":"bibr49-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1007\/s001980170006"},{"key":"bibr50-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.87.2.8299"},{"key":"bibr51-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2003.10.063"},{"key":"bibr52-CMO.S8511","volume-title":"Prevention and management of osteoporosis: report of a WHO scientific group.","author":"World Health Organization.","year":"2003"},{"key":"bibr53-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23084"},{"key":"bibr54-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-009-0920-3"},{"key":"bibr55-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.50"},{"key":"bibr56-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08657-9"},{"key":"bibr57-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(97)90022-X"},{"key":"bibr58-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1007\/s001980050063"},{"key":"bibr59-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)09075-8"},{"key":"bibr60-CMO.S8511","author":"Smith M.","year":"2009","journal-title":"Highlights of the Joint ECCO 15\/34th ESMO Multidisciplinary Congress"},{"key":"bibr61-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.061113"},{"key":"bibr62-CMO.S8511","volume-title":"Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: technical report 843","author":"World Health Organization.","year":"1994"},{"key":"bibr63-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.5650090802"},{"key":"bibr64-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-011-1713-z"},{"key":"bibr65-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dji002"},{"key":"bibr66-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.06.091"},{"key":"bibr67-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.20.3.850"},{"key":"bibr68-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp050045.p2"},{"key":"bibr69-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdm442"},{"key":"bibr70-CMO.S8511","unstructured":"Amgen Inc. PROLIA (denosumab) full prescribing information, May 20, 2012. http:\/\/pi.amgen.com\/united_states\/prolia\/prolia_pi.pdf. Accessed Jun 14, 2012."},{"key":"bibr71-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq422"},{"key":"bibr72-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-11-384"},{"key":"bibr73-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2006.03.022"},{"key":"bibr74-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.9.6.1013"},{"key":"bibr75-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-008-0005-z"},{"key":"bibr76-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2007-0152"},{"key":"bibr77-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-005-0860-1"},{"key":"bibr78-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.1233"},{"key":"bibr79-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn164"},{"key":"bibr80-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-5101"},{"key":"bibr81-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2006.2002"},{"key":"bibr82-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.10-90001-19"},{"key":"bibr83-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1210\/edrv.19.1.0325"},{"key":"bibr84-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-146-6-200703200-00006"},{"key":"bibr85-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.1783"},{"key":"bibr86-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1186\/bcr2565"},{"key":"bibr87-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.24.5902"},{"key":"bibr88-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-2042.2007.01911.x"},{"key":"bibr89-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-009-0655-x"},{"key":"bibr90-CMO.S8511","unstructured":"Merck & Co. I. Fosamax (alendronate sodium) tablets and oral solution full prescribing information, Jul 2011"},{"key":"bibr91-CMO.S8511","unstructured":"Warner Chilcott Company L. Actonel (risedronate sodium) tablets full prescribing information, Feb 2011."},{"key":"bibr92-CMO.S8511","unstructured":"Roche Laboratories I. Boniva (ibandronate sodium) tablets and solution for infection, full prescribing information, Jan 2011."},{"key":"bibr93-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa010845"},{"key":"bibr94-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-009-0332-2"},{"key":"bibr95-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2006.04.078"},{"key":"bibr96-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.4707"},{"key":"bibr97-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.7102"},{"key":"bibr98-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2009.24"},{"key":"bibr99-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.3816\/CBC.2009.n.015"},{"key":"bibr100-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq217"},{"key":"bibr101-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2010.11.024"},{"key":"bibr102-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.3816\/CGC.2007.n.003"},{"key":"bibr103-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-1366"},{"key":"bibr104-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2009.12.001"},{"key":"bibr105-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2009.11.083"},{"key":"bibr106-CMO.S8511","first-page":"5170","volume":"17","author":"Casey R.","year":"2010","journal-title":"Can J Urol."},{"key":"bibr107-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2005.05.035"},{"key":"bibr108-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000063820.94994.95"},{"key":"bibr109-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2009.07.046"},{"key":"bibr110-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.3744"},{"key":"bibr111-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23259"},{"key":"bibr112-CMO.S8511","unstructured":"Novartis Pharmaceuticals Corporation. Reclast (zoledronic acid) injection, Aug 2011."},{"key":"bibr113-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-032058"},{"key":"bibr114-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2007.08.137"},{"key":"bibr115-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2010.06.022"},{"key":"bibr116-CMO.S8511","unstructured":"GTX I. GTx provides corporate update and reports first quarter 2011 financial results. 2011; http:\/\/phx.corporate-ir.net\/phoenix.zhtml?c=148196&p=irol-newsArticle_print&ID=1561101&highlight=. Accessed Mar 2, 2012."},{"key":"bibr117-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2010.08.094"},{"key":"bibr118-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)15493-7"},{"key":"bibr119-CMO.S8511","unstructured":"Novartis Pharmaceuticals Corporation. Miacalcin (calcitonen salmon) (injection or nasal spray) full prescribing information Jul 2011."},{"key":"bibr120-CMO.S8511","unstructured":"Eli Lilly and Company. Forteo (teriparatide injection) full prescribing information, Jan 2010."},{"key":"bibr121-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200105103441904"},{"key":"bibr122-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-004-1713-3"},{"key":"bibr123-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1359\/JBMR.040305"},{"key":"bibr124-CMO.S8511","unstructured":"Amgen Inc. XGEVA (denosumab) full prescribing information. Jun 2012. http:\/\/pi.amgen.com\/united_states\/xgeva\/xgeva_pi.pdf. Accessed Jun 14, 2012."},{"key":"bibr125-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.3832"},{"key":"bibr126-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0809003"},{"key":"bibr127-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2009.08.048"},{"key":"bibr128-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.492"},{"key":"bibr129-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-009-0352-y"},{"key":"bibr130-CMO.S8511","author":"Papapoulos S.","year":"2011","journal-title":"J Bone Miner Res."},{"key":"bibr131-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)62344-6"},{"key":"bibr132-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.7101"},{"key":"bibr133-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61226-9"},{"key":"bibr134-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.2165\/11594240-000000000-00000"},{"key":"bibr135-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.2165\/11598090-000000000-00000"},{"key":"bibr136-CMO.S8511","doi-asserted-by":"publisher","DOI":"10.1016\/S1359-6446(05)03638-X"}],"container-title":["Clinical Medicine Insights: Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.4137\/CMO.S8511","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.4137\/CMO.S8511","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.4137\/CMO.S8511","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T05:53:00Z","timestamp":1777614780000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.4137\/CMO.S8511"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":136,"alternative-id":["10.4137\/CMO.S8511"],"URL":"https:\/\/doi.org\/10.4137\/cmo.s8511","relation":{},"ISSN":["1179-5549","1179-5549"],"issn-type":[{"value":"1179-5549","type":"print"},{"value":"1179-5549","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,1]]},"article-number":"CMO.S8511"}}